文献速递冠心病

新一代超薄支架药物洗脱支架对比老二代厚支架药物洗脱支架治疗冠心病

Newer-Generation Ultrathin Strut Drug-Eluting Stents Versus Older Second-Generation Thicker Strut Drug-Eluting Stents for Coronary Artery Disease.
PubMed 文献 · Circulation · 2018-01-01

该研究系统检索并荟萃分析了10项随机临床试验,共11 658例接受经皮冠状动脉介入治疗的患者,比较新一代超薄支架药物洗脱支架(支架厚度<70 µm)与较厚支架第二代药物洗脱支架的临床结局。主要终点为1年靶病变失败。结果显示,超薄支架组靶病变失败风险降低16%(RR 0.84,95%CI 0.72-0.99),主要由心肌梗死减少驱动(RR 0.80,95%CI 0.65-0.99);任何支架血栓发生率呈定性降低(RR 0.72,95%CI 0.51-1.01)。亚组分析未显示显著异质性。

要点

  • 超薄支架药物洗脱支架较厚支架二代药物洗脱支架降低1年靶病变失败风险。
  • 心肌梗死减少是靶病变失败降低的主要驱动因素。
  • 支架血栓发生率呈定性降低,但置信区间较宽。

核心结论

  • 在接受经皮冠状动脉介入治疗的患者中,新一代超薄支架药物洗脱支架较当代较厚支架第二代药物洗脱支架进一步改善1年临床结局。

研究设计与样本

  • 系统检索PubMed、Embase和Cochrane Central Register of Controlled Trials,纳入比较新一代超薄支架药物洗脱支架(支架厚度<70 µm)与较厚支架第二代药物洗脱支架并报告临床结局的随机临床试验,共纳入10项试验、11 658例随机患者。

主要发现

  • 与较厚支架第二代药物洗脱支架相比,新一代超薄支架药物洗脱支架与靶病变失败风险降低16%相关(RR 0.84,95%CI 0.72-0.99)。
  • 心肌梗死风险降低(RR 0.80,95%CI 0.65-0.99)。
  • 任何支架血栓发生率呈定性降低(RR 0.72,95%CI 0.51-1.01)。
  • 基于超薄支架药物洗脱支架类型的亚组效应检验P=0.58,基于对照药物洗脱支架类型的亚组效应检验P=0.98,均不显著。

关键数值与推荐

  • 超薄支架药物洗脱支架定义为支架厚度<70 µm。
  • 评估的3种新一代超薄支架药物洗脱支架为Orsiro支架(60 μm)、MiStent(64 μm)和BioMime(65 µm)。
  • 主要终点为1年随访时评估的靶病变失败(心血管死亡、靶血管心肌梗死或缺血驱动的靶病变血运重建的复合终点)。

临床怎么用

  • 在接受经皮冠状动脉介入治疗的冠心病患者中,可考虑优先选用新一代超薄支架药物洗脱支架以降低1年靶病变失败和心肌梗死风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Contemporary second-generation drug-eluting stents (DES) have superior efficacy and safety in comparison with early-generation stents in patients undergoing percutaneous coronary intervention, in part, related to their thinner struts. Whether newer-generation ultrathin DES further improve clinical outcomes in comparison with older second-generation thicker strut DES is unknown. METHODS: We searched PubMed, Embase, and Cochrane Central Register of Controlled Trials for randomized clinical trials that compared newer-generation ultrathin strut DES (defined as strut thickness <70 µm) versus thicker strut second-generation DES and reported clinical outcomes. The primary outcome was target lesion failure (composite of cardiovascular death, target vessel myocardial infarction or ischemia-driven target lesion revascularization) evaluated at 1-year follow-up. Tests for subgroup effects based on the ultrathin strut DES type and the comparator DES type were performed by using meta-regression analysis. RESULTS: We identified 10 trials that randomly assigned 11 658 patients and evaluated 3 newer-generation ultrathin strut DES: Orsiro stent (60 μm), MiStent (64 μm), and BioMime (65 µm). In comparison with thicker strut second-generation DES, newer-generation ultrathin strut DES were associated with a 16% reduction in target lesion failure (relative risk, 0.84; 95% CI, 0.72-0.99) driven by less myocardial infarction (relative risk, 0.80; 95% CI, 0.65-0.99). Ultrathin strut DES were also associated with qualitatively lower rates of any stent thrombosis (relative risk, 0.72; 95% CI, 0.51-1.01). Tests for subgroup effects based on the ultrathin strut DES type ( P=0.58) and the comparator DES type ( P=0.98) were not significant, suggesting consistent outcomes across the 3 ultrathin strut DES and with the different DES comparators. CONCLUSIONS: In patients undergoing percutaneous coronary intervention, newer-generation ultrathin strut DES further improve 1-year clinical outcomes in comparison with contemporary thicker strut second-generation DES.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Bangalore S, Toklu B, Patel N, et al. Newer-Generation Ultrathin Strut Drug-Eluting Stents Versus Older Second-Generation Thicker Strut Drug-Eluting Stents for Coronary Artery Disease. Circulation. 2018. PMID: 29945934. doi:10.1161/CIRCULATIONAHA.118.034456

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。